Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) is making waves in the biotechnology industry as one of the penny stocks with the potential to rise by a whopping 1000 percent. This promising company recently received FDA approval for KRESLADI, a groundbreaking gene therapy for a rare pediatric disorder. This approval marks a significant milestone for Rocket Pharmaceuticals, as it not only gives them their first marketed product but also establishes KRESLADI as the first FDA-approved gene therapy for this specific condition.
The FDA approval also came with an additional bonus for Rocket Pharmaceuticals – a Rare Pediatric Disease Priority Review Voucher. This valuable asset can be monetized by biotech companies, and Rocket Pharmaceuticals is currently exploring strategic options to leverage this voucher to enhance their financial flexibility. In addition to this, the company plans to make KRESLADI available to eligible patients in the United States.
Rocket Pharmaceuticals is taking a measured approach to the commercial launch of KRESLADI, focusing on a scaled effort tailored to the very small patient population. The company aims to roll out the therapy through a limited number of specialized centers, ensuring that patients receive the best possible care. As of December 31, 2025, Rocket Pharmaceuticals had $188.9 million in cash, cash equivalents, and investments, providing them with a solid financial foundation to support their growth initiatives.
Rocket Pharmaceuticals is a biotechnology company that specializes in genetic therapies for rare disorders. Their pipeline includes lentiviral and AAV-based programs targeting immunologic and cardiovascular diseases. While the potential for RCKT as an investment is significant, there are other AI stocks that offer even greater upside potential with lower downside risk.
For investors looking for undervalued AI stocks that could benefit from current market trends, it’s worth exploring the best short-term AI stock highlighted in our free report. Follow Insider Monkey on Google News for the latest updates and insights on the stock market.
